Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines

Clinical and Vaccine Immunology

Volumn 14, Issue 7, 2007, Pages 830-838

  Wedege, E ^a   Bolstad, K ^a   Aase, A ^a   Herstad, T K ^a   McCallum, L ^b   Rosenqvist, E ^a   Oster, P ^c   Martin, D ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; LIPOPOLYSACCHARIDE; MEMBRANE ANTIGEN; MENINGOCOCCUS VACCINE; NEISSERIA SURFACE PROTEIN A; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; MENINGOCOCCAL GROUP B POLYSACCHARIDE; NSPA PROTEIN, NEISSERIA; OUTER MEMBRANE PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BLOOD GROUP TYPING; CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MEMBRANE VESICLE; MENINGOCOCCOSIS; NEW ZEALAND; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION; ADOLESCENT; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; MIDDLE AGED; NEISSERIA MENINGITIDIS;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND; PHAGOCYTOSIS; POLYSACCHARIDES, BACTERIAL;

EID: 35748940282     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00039-07     Document Type: Article

References (70)

1. Aase, A., G. Bjune, E. A. Hoiby, E. Rosenqvist, A. K. Pedersen, and T. E. Michaelsen. 1995. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect. Immun. 63:3531-3536.
2. Aase, A. T. K. Herstad, L. M. Næss, T. E. Michaelsen, and D. R. Martin. 2004. Abstr. 14th Int. Pathogenic Neisseria Conf., p. 140.
3. Aase, A., E. A. Hoiby, and T. E. Michaelsen. 1998. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 47:388-396.
4. Aase, A., L. M. Naess, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L. Haugen, E. A. Hoiby, and T. E. Michaelsen. 2003. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 21:2042-2051.
5. Ala'aldeen, D. A., H. A. Davies, and S. P. Borriello. 1994. Vaccine potential of meningococcal FrpB: studies on surface exposure and functional attributes of common epitopes. Vaccine 12:535-541.
6. Andersen, S. R., G. Bjune, J. Lyngby, K. Bryn, and E. Jantzen. 1995. Short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis of potential value for production of outer membrane vesicle vaccines. Microb. Pathog. 19:159-168.
7. Bjune, G., E. A. Hoiby, J. K. Gronnesby, O. Arnesen, J. Holst Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nokleby, E. Rosenqvist, L. K. Solberg, O. Closs, J. Eng, L. O. Froholm, A. Lystad, L. S. Bakketeig, and B. Hareide. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
8. Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 23:2222-2227.
9. Bos, M. P., B. Tefsen, P. Voet, V. Weynants, J. P. van Putten, and J. Tommassen. 2005. Function of neisserial outer membrane phospholipase A in autolysis and assessment of its vaccine potential. Infect. Immun. 73:2222-2231.
10. Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, and J. Mays. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15-P1.3) outer-membrane protein vaccine in Iquique, Chile. Vaccine 13:821-829.
11. Clarke, S. C., M. A. Diggle, P. Molling, M. Unemo, and P. Olcen. 2003. Analysis of PorA variable region 3 in meningococci: implications for vaccine policy? Vaccine. 21:2468-2473.
12. de Jonge, M. I., M. P. Bos, H. J. Hamstra, W. Jiskoot, P. van Ulsen, J. Tommassen, L. van Alphen, and L. P. van der Ley. 2002. Conformational analysis of opacity proteins from Neisseria meningitidis. Eur. J. Biochem. 269:5215-5223.
13. de Moraes, J. C., B. A. Perkins, M. C. C. Camargo, N. T. R. Hidalgo, H. A. Barbosa, C. T. Sacchi, I. M. L. Gral, V. L. Gattas, H. D. Vasconcelos, B. D. Plikaytis, J. D. Wenger, and C. V. Broome. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao-Paulo, Brazil. Lancet 340:1074-1078.
14. Devoy, A. F., K. H. Dyet, and D. R. Martin. 2005. Stability of PorA during a meningococcal disease epidemic. J. Clin. Microbiol. 43:832-837.
15. Dyet, K. H., and D. R. Martin. 2005. Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic. J. Clin. Microbiol. 43:838-842.
16. Dyet, K. H., and D. R. Martin. 2006. Clonal analysis of the serogroup B meningococci causing New Zealand's epidemic. Epidemiol. Infect. 134:377-383.
17. Ferrari, G., I. Garaguso, J. Adu-Bobie, F. Doro, A. R. Taddei, A. Biolchi, B. Brunelli, M. M. Giuliani, M. Pizza, N. Norais, and G. Grandi. 2006. Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 6:1856-1866.
18. Findlow, J., S. Taylor, A. Aase, R. Horton, R. Heyderman, J. Southern, N. Andrews, R. Barchha, E. Harrison, A. Lowe, E. Boxer, C. Heaton, P. Balmer, E. Kaczmarski, P. Oster, A. Gorringe, R. Borrow, and E. Miller. 2006. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect. Immun. 74:4557-4565.
19. Frasch, C., G. Coetzee, J. M. Zahadrik, H. A. Feldman, and H. J. Kornhoof. 1983. Development and evaluation of group B serotype 2 protein vaccines: report of a group B field trial. Med. Trop. (Marseille) 43:177-180.
20. Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Froholm, A. K. Lindbak, B. Mogster, E. Namork, U. Rye, G. Stabbetorp, R. Winsnes, A. Aase, and O. Closs. 1991. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann. 14:67-79.
21. Gomez, J. A., M. T. Criado, and C. M. Ferreiros. 1998. Bactericidal activity of antibodies elicited against the Neisseria meningitidis 37-kDa ferric binding protein (FbpA) with different adjuvants. FEMS Immunol. Med. Microbiol. 20:79-86.
22. Halperin, S. A., J. M. Langley, B. Smith, P. Wunderli, L. Kaufman, A. Kimura, and D. Martin. 2007. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine 25:450-457.
23. Hoiby, E. A., E. Rosenqvist, L. O. Froholm, G. Bjune, B. Feiring, H. Nokleby, and E. Ronnild. 1991. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann. 14:147-155.
24. Holst, J. 2006. A 'taylor made' vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Eurosurv. Wkly. http:\www.eurosurveillance.org/ew/2003/031016.asp#1.
25. Holst, J., B. Feiring, L. M. Naess, G. Norheim, P. Kristiansen, E. A. Hoiby, K. Bryn, P. Oster, P. Costantino, M. K. Taha, J. M. Alonso, D. A. Caugant, E. Wedege, I. S. Aaberge, R. Rappuoli, and E. Rosenqvist. 2005. The concept of "tailor-made," protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine 23:2202-2205.
26. Humphries, H. E., J. N. Williams, R. Blackstone, K. A. Jolley, H. M. Yuen, M. Christodoulides, and J. E. Heckels. 2006. Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis. Vaccine 24:36-44.
27. Idanpaan-Heikkila, I., E. A. Hoiby, P. Chattopadhyay, U. Airaksinen, T. M. Michaelsen, and E. Wedege. 1995. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J. Med. Microbiol. 43:335-343.
28. Jansen, C., A. Wiese, L. Reubsaet, N. Dekker, H. de Cock, U. Seydel, and J. Tommassen. 2000. Biochemical and biophysical characterization of in vitro folded outer membrane porin PorA of Neisseria meningitidis. Biochim. Biophys. Acta 1464:284-298.
29. Jennings, M. P., Y. N. Srikhanta, E. R. Moxon, M. Kramer, J. T. Poolman, B. Kuipers, and P. van der Ley. 1999. The genetic basis of the phase variation repertoire of lipopolysaccharide immunotypes in Neisseria meningitidis. Microbiology 145(Pt 11):3013-3021.
30. Kortekaas, J., S. A. Muller, P. Ringler, M. Gregorini, V. E. Weynants, L. Rutten, M. P. Bos, and J. Tommassen. 2006. Immunogenicity and structural characterisation of an in vitro folded meningococcal siderophore receptor (FrpB, FetA). Microbes Infect. 8:2145-2153.
31. Kortekaas, J., A. Pettersson, J. van der Biezen, V. E. Weynants, P. van der Ley, J. Poolman, M. P. Bos, and J. Tommassen. 2007. Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region. Vaccine 25:72-84.
32. Kristiansen, P. A., I. S. Aaberge, K. Møyner, L. M. Næss, K. Bryn, K. Nord, A. G. Skryten, E. Namork, E. Rosenqvist, and K. Harbak. 2002. Abstr. 13th Int. Pathogenic Neisseria Conf., p. 268.
33. Mandrell, R. E., and W. D. Zollinger. 1984. Use of a zwitterionic detergent for the restoration of the antibody-binding capacity of electroblotted meningococcal outer membrane proteins. J. Immunol. Methods 67:1-11.
34. Martin, D., N. Cadieux, J. Hamel, and B. R. Brodeur. 1997. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J. Exp. Med. 185:1173-1183.
35. Martin, D., L. McCallum, A. Glennie, N. Ruijne, P. Blatchford, J. O'Hallahan, and P. Oster. 2005. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine 23:2218-2221.
36. Martin, D. R., N. Ruijne, L. McCallum, J. O'Hallahan, and P. Oster. 2006. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin. Vaccine Immunol. 13:486-491.
37. McGuinness, B. T., P. R. Lambden, and J. E. Heckels. 1993. Class 1 outer membrane protein of Neisseria meningitidis: epitope analysis of the antigenic diversity between strains, implications for subtype definition and molecular epidemiology. Mol. Microbiol. 7:505-514.
38. Michaelsen, T. E., A. Aase, J. Kolberg, E. Wedge, and E. Rosenqvist. 2001. PorB3 outer membrane protein on Neisseria meningitidis is poorly accessible for antibody binding on live bacteria. Vaccine 19:1526-1533.
39. Milagres, L. G., S. R. Ramos, C. T. Sacchi, C. E. Melles, V. S. Vieira, H. Sato, G. S. Brito, J. C. Moraes, and C. E. Frasch. 1994. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun. 62:4419-4424.
40. Moe, G. R., S. Tan, and D. M. Granoff. 1999. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect. Immun. 67:5664-5675.
41. Naess, L. M., T. Aarvak, A. Aase, F. Oftung, E. A. Hoiby, R. Sandin, and T. E. Michaelsen. 1999. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 17:754-764.
42. Norheim, G., A. Aase, D. A. Caugant, E. A. Hoiby, E. Fritzsonn, T. Tangen, P. Kristiansen, U. Heggelund, and E. Rosenqvist. 2005. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis. Vaccine 23:3762-3774.
43. O'Hallahan, J., D. Lennon, P. Oster, R. Lane, S. Reid, K. Mulholland, J. Stewart, L. Penney, T. Percival, and D. Martin. 2005. From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal disease. Vaccine 23:2197-2201.
44. Rosenqvist, E., K. Bryn, K. Harbak, J. Holst, E. A. Høiby, P. Kristiansen, H. Lange, D. Martin, K. Møyner, K. Nord, L. M. Næss, A. G. Skryten, I. Aaberge, A. Aase, and H. Nøkleby. 2002. Abstr. 13th Int. Pathogenic Neisseria Conf., p. 64.
45. Rosenqvist, E., E. A. Hoiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Ronnild, G. Bjune, and H. Nokleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
46. Rosenqvist, E., E. A. Hoiby, E. Wedege, B. Kusecek, and M. Achtman. 1993. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J. Infect. Dis. 167:1065-1073.
47. Rosenqvist, E., A. Musacchio, A. Aase, E. A. Hoiby, E. Namork, J. Kolberg, E. Wedege, A. Delvig, R. Dalseg, T. E. Michaelsen, and J. Tommassen. 1999. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Infect. Immun. 67:1267-1276.
48. Ross, S. C., P. J. Rosenthal, H. M. Berberich, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis. 155:1266-1275.
49. Ruijne, N., R. A. Lea, J. O'Hallahan, P. Oster, and D. Martin. 2006. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Clin. Vaccine Immunol. 13:797-801.
50. Scholten, R. J., B. Kuipers, H. A. Valkenburg, J. Dankert, W. D. Zollinger, and J. T. Poolman. 1994. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol. 41:236-243.
51. Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-207.
52. Thompson, E. A., I. M. Feavers, and M. C. Maiden. 2003. Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component. Microbiology 149:1849-1858.
53. Thornton, V., D. Lennon, K. Rasanathan, J. O'Hallahan, P. Oster, J. Stewart, S. Tilman, I. Aaberge, B. Feiring, H. Nokleby, E. Rosenqvist, K. White, S. Reid, K. Mulholland, M. J. Wakefield, and D. Martin. 2006. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24:1395-1400.
54. Toropainen, M., L. Saarinen, E. Wedege, K. Bolstad, P. H. Makela, and H. Kayhty. 2005. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines. Vaccine 23:4821-4833.
55. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
56. van der Ley, P., J. van der Biezen, R. Sutmuller, P. Hoogerhout, and J. T. Poolman. 1996. Sequence variability of FrpB, a major iron-regulated outer-membrane protein in the pathogenic neisseriae. Microbiology 142(Pt 11):3269-3274.
57. van der Voort, E. R., P. van der Ley, J. van der Biezen, S. George, O. Tunnela, H. van Dijken, B. Kuipers, and J. Poolman. 1996. Specificity of human bactericidal antibodies against PorA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect. Immun. 64:2745-2751.
58. Vermont, C. L., H. H. van Dijken, A. J. Kuipers, C. J. van Limpt, W. C. Keijzers, A. van der Ende, R. de Groot, L. van Alphen, and G. P. van den Dobbelsteen. 2003. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine. Infect. Immun. 71:1650-1655.
59. Vipond, C., J. X. Wheeler, I. M. Feavers, J. Suker, and C. Jones. 2005. Characterization of the protein content of a meningococcal outer membrane vesicle vaccine by polyacrylamide gel electrophoresis and mass spectrometry. Hum. Vaccine 1:80-84.
60. Vipond, C., J. Suker, C. Jones, C. Tang, I. M. Feavers, and J. X. Wheeler. 2006. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 6:3400-3413.
61. Wedege, E. 2001. Immunoblot analysis of sera from patients and vaccinees, p. 275-288. In A. J. Pollard and M. C. J. Maiden (ed.), Meningococcal vaccines: methods and protocols. Humana Press, Totowa, NJ.
62. Wedege, E., I. Aaberge, K. Bolstad, E. Fritzsønn, U. Heggelund, L. McCallum, L. M. Næss, E. Rosenqvist, and D. Martin. 2004. Abstr. 14th Int. Pathogenic Neisseria Conf., p. 196.
63. Wedege, E., K. Bryn, and L. O. Froholm. 1988. Restoration of antibody binding to blotted meningococcal outer membrane proteins using various detergents. J. Immunol. Methods 113:51-59.
64. Wedege, E., R. Dalseg, D. A. Caugant, J. T. Poolman, and L. O. Froholm. 1993. Expression of an inaccessible P1.7 subtype epitope on meningococcal class 1 proteins. J. Med. Microbiol. 38:23-28.
65. Wedege, E., and L. O. Froholm. 1986. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect. Immun. 51:571-578.
66. Wedege, E., E. A. Hoiby, E. Rosenqvist, and G. Bjune. 1998. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun. 66:3223-3231.
67. Wedege, E., B. Kuipers, K. Bolstad, H. van Dijken, L. O. Froholm, C. Vermont, D. A. Caugant, and G. van den Dobbelsteen. 2003. Antibody specificities and effect of meningococcal carriage in Icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine. Infect. Immun. 71:3775-3781.
68. Wu, L. H., C. M. Tsai, and C. E. Frasch. 1987. A method for purification of bacterial R-type lipopolysaccharides (lipooligosaccharides). Anal. Biochem. 160:281-289.
69. Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-521.
70. Zollinger, W., E. Moran, D. Schmiel, and B. Brandt. 2006. Abstr. 15th Int. Pathogenic Neissseria Conf., abstr. P8.3.19.